Stocks · News reference
NeuroSense Therapeutics announced it will present integrated clinical and biomarker findings that are informing the next phase of development for its lead ALS drug candidate, PrimeC, at the 2026 NEALS Consortium Annual Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
NeuroSense Therapeutics announced it will delay its New Drug Submission (NDS) for PrimeC to March 2027 to incorporate new neurofilament light chain (NfL) analysis and additional Phase 2b data.
HC Wainwright & Co. downgraded NeuroSense Therapeutics from Buy to Neutral on November 2, 2026.
The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases,